The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma
Open Access
- 1 January 2019
- journal article
- research article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 10 (14) , 3140-3144
Abstract
Background: Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a heterogeneous disease in terms of embryonic origin, aggressiveness, prognosis, and genomic profiling. Data regarding the efficacy of etoposide and cisplatin (EP) as a standard treatment of the primary tumor site in GEP-NEC are limited.Keywords
This publication has 20 references indexed in Scilit:
- Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinomaGastric Cancer, 2011
- Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and PancreasJapanese Journal of Clinical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumoursEndocrine-Related Cancer, 2008
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors – Well-Differentiated Jejunal-Ileal Tumor/CarcinomaNeuroendocrinology, 2007
- Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine TumorsClinical Cancer Research, 2007
- Aggressive Surgery Improves Long-term Survival in Neuroendocrine Pancreatic TumorsAnnals of Surgery, 2007
- Chemotherapy for Gastro-Enteropancreatic Endocrine TumoursNeuroendocrinology, 2004
- THE CLASSIFICATION OF CARCINOID TUMOURSThe Lancet, 1963